ORIGINAL PAPER
B-type natriuretic peptide and high sensitivity C-reactive protein in patients with rheumatic fever and rheumatic heart disease: relationship to mitral regurgitation
1
Department of Pediatrics, National Research Centre, Cairo, Egypt
2
Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
3
Department of Clinical and Chemical Pathology, National Research Centre, Cairo, Egypt
Submission date: 2020-09-04
Final revision date: 2020-10-17
Acceptance date: 2020-10-18
Publication date: 2021-01-30
Pediatr Pol 2020;95(4):234-240
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Rheumatic fever (RF) is one of the leading causes of cardiac disease in developing countries. Brain natriuretic peptide (BNP) is a cardiovascular hormone emitted from the myocardium of the ventricles as a reaction to pressure overload and the expansion of ventricular volume. High sensitivity C reactive protein (hsCRP) levels are increased in several inflammatory and cardiac diseases. We aimed to study the relationship between BNP and hsCRP levels and the presence of rheumatic heart disease (RHD) and to investigate their levels as indices of the severity of chronic rheumatic mitral regurgitation (MR).
Material and methods:
Seventy-seven Egyptian patients with RF and 43 age and gender-matched healthy controls were included in the study. The two groups of the RF patients were: RHD, group (n = 62) diagnosed by transthoracic echocardiogram detecting the rheumatic involvement of the mitral valve, and rheumatic fever only (RFo) group (n = 15) had a history of RF without the presence of RHD. Serum BNP levels were measured by enzyme-linked immunoassay, while hsCRP levels were measured by the immunometric assay.
Results:
Both serum BNP and hsCRP levels were higher in RHD groups than in the controls (p = 001 and p = 0.018, respectively). Serum BNP levels were elevated in the RHD patients than in the RFo patients (p = 0.01). Both BNP and hsCRP levels were correlated positively with echocardiographic parameters of the severity of MR (p = 0.001). The cut-off value of BNP levels of 9.02 ng/ml with sensitivity 67.7% and specificity 85.4% was associated with the risk of RHD. No correlation was found between BNP levels and the duration of RHD.
Conclusions:
The serum BNP levels and hsCRP levels appear to be significantly associated with the RHD and the MR severity.
Rheumatic fever (RF) is one of the leading causes of cardiac disease in developing countries. Brain natriuretic peptide (BNP) is a cardiovascular hormone emitted from the myocardium of the ventricles as a reaction to pressure overload and the expansion of ventricular volume. High sensitivity C reactive protein (hsCRP) levels are increased in several inflammatory and cardiac diseases. We aimed to study the relationship between BNP and hsCRP levels and the presence of rheumatic heart disease (RHD) and to investigate their levels as indices of the severity of chronic rheumatic mitral regurgitation (MR).
Material and methods:
Seventy-seven Egyptian patients with RF and 43 age and gender-matched healthy controls were included in the study. The two groups of the RF patients were: RHD, group (n = 62) diagnosed by transthoracic echocardiogram detecting the rheumatic involvement of the mitral valve, and rheumatic fever only (RFo) group (n = 15) had a history of RF without the presence of RHD. Serum BNP levels were measured by enzyme-linked immunoassay, while hsCRP levels were measured by the immunometric assay.
Results:
Both serum BNP and hsCRP levels were higher in RHD groups than in the controls (p = 001 and p = 0.018, respectively). Serum BNP levels were elevated in the RHD patients than in the RFo patients (p = 0.01). Both BNP and hsCRP levels were correlated positively with echocardiographic parameters of the severity of MR (p = 0.001). The cut-off value of BNP levels of 9.02 ng/ml with sensitivity 67.7% and specificity 85.4% was associated with the risk of RHD. No correlation was found between BNP levels and the duration of RHD.
Conclusions:
The serum BNP levels and hsCRP levels appear to be significantly associated with the RHD and the MR severity.
REFERENCES (31)
1.
Carapetis JR, Zühlke LJ.; Global research priorities in rheumatic fever and rheumatic heart disease. Ann Pediatr Cardiol 2011; 4: 4-12.
3.
Yau TM, El-Ghoneimi YA, Armstrong S, et al. Mitral valve repair and replacement for rheumatic disease. J Thorac Cardiovasc Surg 2000; 119: 53-60.
4.
Anam A, Faisal AWK, Afzal N, et al. Immune system activation in rheumatic heart disease. J Coll Physicians Surg Pak 2018; 28: 518-522.
5.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70: 252-289.
6.
Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: The Global Rheumatic Heart Disease Registry (the REMEDY study) Eur Heart J 2015; 36: 1115-1122.
7.
Zachariah JP, Samnaliev M. Echo-based screening of rheumatic heart disease in children: A cost-effectiveness Markov model. J Med Econ 2015; 18: 410-419.
8.
Zachariah JP, Aliku T, Scheel A,et al. Amino-terminal pro-brain natriuretic peptide in children with latent rheumatic heart disease. Ann Pediatr Cardiol 2016; 9: 120.
9.
Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177-2187.
10.
Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem 2005; 40: 1-36.
11.
Yap LB, Mukerjee D, Timms PM, et al. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126: 1330-1336.
12.
Dickstein K, Larsen AI, Bonarjee V, et al. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol 1995; 76: 679-6783.
13.
Mostafa FA,. Sad IA.E.S, Elshamaa MF, et al. Left ventricular dysfunction by conventional and tissue Doppler echocardiography in pediatric hemodialysis patients: relation with plasma brain natriuretic peptide levels. Arch Med Sci Atheroscler Dis 2018; 3: e18-e28.
14.
Watanabe M, Murakami M, Furukawa H, et al. Is measurement of plasma brain natriuretic peptide levels a useful test to detect for surgical timing of valve disease? Int J Cardiol 2004; 96: 21-24.
15.
Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97: 4239-4244.
16.
Zachariah JP, Aliku T, Scheel A, et al. Amino-terminal pro-brain natriuretic peptide in children with latent rheumatic heart disease. Ann Pediatr Cardiol 2016; 9: 120-125.
17.
Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation 2015; 131: 1806-1818.
18.
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017; 30: 303-371.
19.
Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
20.
Mak GS, DeMaria A, Clopton P, et al. Utility of B-natriureticpeptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 2004; 148: 895-902.
21.
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-617.
22.
Massera D, Kizer JR, Dweck MR. Mechanisms of mitral annular calcification. Trends Cardiovasc Med 2020; 30: 289-295.
23.
Attar A, Aghasadeghi K, Parsanezhad ME, et al. Absence of correlation between changes in the number of endothelial progenitor cell subsets. Korean Circul J 2015; 45: 325-332.
24.
Attar A, Khosravi Maharlooi M, Khoshkhou S, et al. Colony forming unit endothelial cells do not exhibit telomerase alternative splicing variants and activity. Iran Biomed J 2013; 17: 146-151.
25.
Attar A, Marzban P, Moaref A, et al. The association of plasma high-sensitivity C-reactive protein level with rheumatic heart disease: the possible role of inflammation. Indian Heart J 2018; 70: 346-349.
26.
Owens DS, Otto C, Bonow R. Valvular Heart Disease: a Companion to Braunwald’s Heart Disease. Saunders; 2014, 53-62.
27.
Abdel Fattah EM, Girgis HYA, El Khashab K, et al. B-type Natriuretic Peptide as an Index of Symptoms and Severity of Chronic Rheumatic Mitral Regurgitation. Heart Views 2016; 17: 7-12.
28.
Sharma A, Ahmed V, Garg A, Aggarwal C. Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart. Disease Markers 2015; 1-6.
29.
Pizarro R, Bazzino O, Oberti P et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009; 54: 1099-1106.
30.
Meneghelo ZM, Magalhães HM, Ramos AI, et al. Sensitivity and specificity of Btype natriuretic peptide for identifying symptomatic and asymptomatic patients with severe mitral regurgitation. Arq Bras Cardiol 2004; 83: 21-25.
31.
Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003; 41: 2280-2287.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
